Bigspace Investments Ltd

Bigspace Investments is a Cyprus-based early-stage VC investing across pre-seed and seed in a sector-agnostic mandate that explicitly includes medical devices and MedTech. Headquartered in Nicosia and active in the United Kingdom and Cyprus, it sits in a niche of European seed capital that is willing to back hardware-intensive healthcare innovation alongside software, fintech, and consumer plays.

The firm operates with a small-check, high-volume profile typical of regional European seed funds, with stated check sizes of EUR 50K to EUR 500K. For MedTech founders, this is most useful as a syndicate participant rather than a sole lead on a regulatory-heavy device round, given the capital intensity of class II and class III device development. Specific portfolio companies are not disclosed in the input record, and the firm’s online presence is lighter than US peers, so founders should request a recent deal list during initial diligence and confirm current MedTech allocation before investing meeting time.

Check range disclosed is $250K to $1M, deployed across pre-seed and seed only. Geography is concentrated on the United Kingdom and Cyprus, which fits founders building in those markets or planning a UK CE-mark and clinical strategy. There is no LinkedIn page disclosed in the source record, so the firm’s website is the primary outbound channel.

Named partners and team members are not provided in the input record. Founders should research individual partners on LinkedIn and via the firm’s website before initiating contact to ensure their device modality and clinical application maps to a partner’s coverage area.

Approach Bigspace when you are a UK or Cyprus-domiciled MedTech founder raising a sub-EUR 1M seed and looking to fill out a syndicate of European seed funds and angels. They are not the right call for capital-intensive, lead-investor-needed MedTech rounds where a specialist device fund or strategic corporate investor is the better anchor. The most efficient outreach is a warm intro from a portfolio founder or a UK-based MedTech advisor familiar with the firm. When pitching, be clear-eyed about regulatory pathway, expected first commercial market, and how a small early check will be sequenced into a credible Series A plan, because that pragmatism is what differentiates fundable MedTech seed rounds from research projects.